Malattia polmonare cronica

Esiti neonatali e criteri di rimborso per il palivizumab

A. Addis, V. Belleudi, F. Trotta, L. Pinnarelli, M. Davoli

2018/10 — pag. 636-640

In 2016 the Italian Medicines Agency (AIFA) decided to limit the coverage of the prophylaxis with palivizumab following the American Academy of Pediatrics guidelines. In 2017 as a consequence of the strong debate that involved scientific societies, p...

Una broncodisplasia complicata

P. Pascolo, G. Facchina

2015/8

L’eccesso di diagnosi e trattamento per il presunto reflusso gastroesofageo

F. Marchetti

2012/2 — pag. 99-101

La displasia broncopolmonare e la sua gestione domiciliare

Luciano Anfossi, Stefania Fassio, Anna Rita Berghelli

2007/6 — pag. 375-380

Bronchopulmonary dysplasia (BPD) is considered one of the primary causes of chronic lung disease among infants. Pathogenesis is complex, being primarily influenced by prematurity, infection, supplementary oxygen and mechanical ventilation. Prevention...

Il deficit di alfa1-antitripsina in età pediatrica

L. Giglio, I. Berti, C. Trevisiol

2003/3 — pag. 155-161

Alpha 1-antitrypsin deficiency (AATD) is an autosomal recessive disease, with more than 70 genetic variants, and a frequency which varies from 1:1000 to 1:5000, depending on genetic epidemiology and screening methods. The AATD involves primarily th...

A proposito di Palivizumab e pretermineAncora su Medicus MedicorumSull’alitosiPropaganda occultaAcido folico e confezioni farmaceutiche

2000/4 — pag. 218-220